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Background Studies using positron emission tomography to 
image striatal dopamine function, have demonstrated that 
individuals with schizophrenia display increases in presynaptic 
function. Mesolimbic dysfunction specifically, has previously 
been suggested to underlie psychotic symptoms. This has not 
been directly tested in vivo, and the precise anatomical locus 
of dopamine dysfunction within the striatum remains unclear. 
The current article investigates the magnitude of dopaminergic 
abnormalities in individuals with schizophrenia, and determines 
how the magnitude of abnormality varies across functional sub-
divisions of the striatum.  Methods EMBASE, PsychINFO, 
and MEDLINE were searched from January 1, 1960, to 
December 1, 2016. Inclusion criteria were molecular imaging 
studies that had measured presynaptic striatal dopamine func-
tioning. Effects sizes for whole striatum and functional subdivi-
sions were calculated separately. The magnitude of difference 
between functional subdivisions in patients and controls was 
meta-analyzed.  Results Twenty-one eligible studies were iden-
tified, including 269 patients and 313 controls. Individuals with 
schizophrenia (Hedges’ g = 0.68, P < .001) demonstrated ele-
vated presynaptic dopamine functioning compared to controls. 
Seven studies examined functional subdivisions. These demon-
strated significant increases in patients compared to controls 
in associative (g = 0.73, P = .002) and sensorimotor (g = 0.54, 
P = .005) regions, but not limbic (g = 0.29, P = .09). The mag-
nitude of the difference between associative and limbic subdivi-
sions was significantly greater in patients compared to controls 
(g = 0.39, P = .003).  Conclusion In individuals with schizophre-
nia dopaminergic dysfunction is greater in dorsal compared to 
limbic subdivisions of the striatum. This is inconsistent with the 
mesolimbic hypothesis and identifies the dorsal striatum as a 
target for novel treatment development.
Key words:  PET/neuroimaging/nigrostriatal/ 
F-DOPA/amphetamine
Introduction
Dysfunction of the dopamine system is one of the most 
well established findings in schizophrenia.1–4 Initial evi-
dence was mostly indirect: based on preclinical work, 
the behavioral effects of drugs, and post-mortem stud-
ies.5 The development of positron emission tomography 
(PET) and single-photon emission computed tomogra-
phy (SPECT), allowed the dopamine system to be stud-
ied in vivo in individuals with schizophrenia.6 Initial 
studies employed ligands specific to dopamine receptors, 
and allowed the quantification of receptor availability, 
while later work was able to investigate dopamine synthe-
sis and release, and other aspects of dopaminergic func-
tion. Previous meta-analyses of these imaging studies 
have found that the major dopaminergic abnormality in 
schizophrenia is increased presynaptic activity in the stri-
atum.1,3 While an elevation of postsynaptic D2 receptors 
has also been proposed, meta-analytic findings have been 
less convincing,1 although the presynaptic results raise 
the possibility that receptor differences may be masked 
by increased endogenous dopamine levels.7–9
Although cortical dopaminergic functioning has also 
been studied in schizophrenia,10,11 the main anatomical 
focus for investigations of dopamine dysfunction has 
been the striatum. Animal research has demonstrated 
that the striatum can be divided into 3 distinct subregions 
based on function and the predominant topography of 
brain projections from limbic, associative, and sensori-
motor cortical areas to the striatum (figure  1).12,13 The 
antero-ventral striatum receives projections from lim-
bic areas such as the orbital frontal cortex and medial 
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temporal lobe, and consequently has been termed the 
limbic striatum. Anatomically it comprises the nucleus 
accumbens, and ventral parts of the caudate and puta-
men. The associative striatum, involved in higher cogni-
tive function, receives projections primarily from cortical 
regions involved in executive and other higher cognitive 
processes, such as the dorsolateral prefrontal cortex, and 
is made up of the majority of the caudate, and the pre-
commisural putamen. Finally, the sensorimotor striatum, 
involved in sensory and motor processing, receives affer-
ent projections predominantly from sensory, motor, and 
premotor areas and consists of the postcommisural puta-
men. More recent imaging studies have indicated that this 
topography is paralleled in the human brain.14,15
Primarily based on preclinical research, dopaminergic 
hyperactivity of the limbic striatum has long been hypothe-
sized as underlying psychotic symptoms.16–19 In vivo evidence 
for a specific mesolimbic abnormality has, however, been 
lacking. Initial imaging studies did not have sufficient res-
olution to visualize these subdivisions, and so reported val-
ues for either the whole striatum, or the anatomical divisions 
of caudate and putamen. However, improvements in PET 
cameras over the past decade have subsequently allowed 
dopaminergic function to be measured in these functional 
subdivisions. Work undertaken by Laruelle, Mawlawi, 
Martinez and colleagues,20,21 defined these subregions based 
on anatomical landmarks to allow the consistent reporting 
of subdivision findings in PET studies, and Howes, Egerton 
and colleagues determined the reliability of this approach.22 
Initial studies using these functional divisions suggested 
that the greatest abnormality was within the associative stri-
atum.8,23 Several further studies have since been performed, 
but the results have not been meta-analyzed.
In the current article, we aim to test the mesolimbic 
hypothesis by comparing the magnitude of dysfunction 
between the limbic and other striatal subdivisions. We 
also provide an update to previous meta-analyses of stri-
atal dopamine function given that a significant number 
of studies have been published since previous reviews.
Methods
EMBASE, PsychINFO and MEDLINE were searched 
from 1960 (or 1974 in the case of EMBASE), to December 
31, 2016. Titles and abstracts were searched for the words: 
(“schizophrenia” or “psychosis” or “schizophreniform”) 
AND (“Positron Emission Tomography” or “PET” 
or “Single photon emission tomography” or SPET or 
“Single Photon Emission Computed Tomography” or 
SPECT) AND (Dopamine).
For the meta-analysis of  presynaptic dopamine func-
tion in schizophrenia the inclusion criteria were: (1) 
studies of  patients with schizophrenia diagnosed in 
accordance with criteria specified in the Diagnostic and 
Statistical Manual for Mental Disorders (DSM), or the 
International Classification of  Diseases (ICD)24,25 and a 
control group; (2) reporting molecular imaging meas-
ures of  presynaptic dopaminergic function (see supple-
mentary methods for further details) for both the patient 
and control groups; (3) providing data enabling the esti-
mation of  mean difference between control and clinical 
groups for the dopaminergic measure; and (4) For the 
subdivision analysis only studies reporting all 3 subdivi-
sions (limbic, associative, and sensorimotor subdivisions) 
were included to enable comparisons across regions.
Studies reporting data on dopaminergic functioning 
in individuals with treatment resistant schizophrenia, or 
co-morbid substance dependence, were excluded. This is 
because the primary neurobiological abnormality in these 
patients may not involve striatal hyperdopaminergia.26–29
Fig. 1. The topography of cortical afferents to the striatum illustrating the functional subdivisions.
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Data Extraction
The primary outcome of interest was the dopamine imag-
ing parameter reported for the patient and control groups. 
For studies using labeled L-DOPA this was the influx con-
stant in the region of interest relative to uptake in the ref-
erence region, while for studies using a release or depletion 
paradigm this was percent change in binding potential. In 
addition, author, year of study, number of participants, 
participant age and gender, illness duration, antipsychotic 
treatment, symptom scores, scan length, and whether an 
arterial input function was used were extracted.
Two studies23,30 reporting data in individuals with 
schizophrenia were not included due to sample overlap 
with Howes et al 2013.31 Where values for the whole stri-
atum were not given but data for the caudate and puta-
men were reported, whole striatum values were calculated 
as described previously1 by weighting these values by 
their volumes as reported in the Oxford-GSK-Imanova 
Structural–Anatomical Striatal Atlas (43% and 57% 
respectively). If  the ventral striatum was also reported the 
following weightings were used to derive a summary out-
come for the whole striatum: caudate – 36%, putamen-
putamen – 48%, ventral striatum – 16%.32
Statistical Analysis
All statistical analyses were carried out using the “meta-
for” package (version 1.9–9) in the statistical programming 
language R (version 3.3.1). A minimum of 3 studies was 
required for meta-analysis. Standard effect sizes (Hedges’ g) 
for individual studies were estimated. The individual study 
effect sizes were then entered into a random effects meta-
analytic model using restricted maximum likelihood esti-
mation. I2 values were calculated to estimate between study 
heterogeneity. Where there were at least 10 studies included 
in a meta-analysis, funnel plots were constructed and vis-
ually inspected, and Egger’s regression test performed to 
check for the possibility of publication bias.33 Secondary 
subgroup and meta-regression analyses were undertaken 
to investigate the relationship between dopaminergic func-
tion and antipsychotic treatment (studies where ≥75% of 
patients were antipsychotic naïve were grouped as stud-
ies of predominantly antipsychotic naïve patients), scan 
length, paradigm type, modeling techniques, patient age 
and severity of symptoms.34 The statistical significance 
of differences between subgroups was tested for by fitting 
separate random effects models for each subgroup, and 
then comparing the subgroup estimates in a fixed effects 
model with a Wald-type test. A significance level of P < .05 
(2-tailed) was used for all analyses.
To test the hypothesis that dopamine dysfunction is pri-
marily located in limbic regions we first determined if  there 
was a significant difference between patients and controls 
for each individual subdivision. We next calculated the 
magnitude of subdivision differences within group, and 
then determined whether the size of these differences 
significantly differed between groups (see below and sup-
plementary information for further details).
In order to contrast and quantify the degree of dys-
function between subdivisions, a meta-analysis of differ-
ence was undertaken. In this we performed an inter-group 
(patient vs control) comparison of the magnitude of 
intra-group subdivision differences (eg, associative vs lim-
bic). This approach employs methods used to quantify the 
propagation of errors.35 For each study, mean within sub-
ject differences in presynaptic function between subdivi-
sions were calculated for both patient and control groups. 
For example, for patients the mean difference between 
associative and limbic measurements ( )Pal  equals:
P P P
P
P
al a l
a
l
= −
=
=
( )
( )
meanassociativevalue
mean limbic value
In order to calculate the standard deviation of this 
mean difference, a correlation coefficient for presynaptic 
functioning between subdivisions is required (see sup-
plementary information and supplementary eFigure  1 
for full methods).36 We estimated this correlation coef-
ficient from individual data for 37 subjects (21 controls 
and 16 individuals with schizophrenia).37 This showed 
Pearson’s coefficients of 0.72, 0.84, and 0.87 for corre-
lations between sensorimotor-limbic, associative-limbic, 
and associative-sensorimotor divisions respectively. To be 
conservative the lowest of these values (0.72) was used for 
all comparisons. For example, to calculate the standard 
deviation of the limbic-associative difference in a patient 
group35:
σ σ σ σ σ
σ
P P P P P
P
al a l a l
al
ral= + −
=
2 2 2
Standard deviation of limbic −
=
associative 
difference
 Standard deviation of associaσPa tive 
subdivision values
 Standard deviation of limbic σPl = subdivision values
 Correlation between limbic and assral = ociative 
subdivision values
We repeated the exercise to calculate the control mean 
difference ( ),Cal  and standard deviation ( ),σCal  and 
then calculated the combined standard deviation of both 
groups ( )σPCal .
σ
σ σ
PC
P P C C
P C
al
al al
n n
n n
=
− + −
+ −
( ) ( )1 1
2
2 2
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nP = Number of patients
nC = Number of controls
The between groups effect size for the study was then cal-
culated for each subdivision using this standard deviation 
as follows:
ES
P Cal al
PCal
=
−
σ
This was converted to the bias corrected Hedges g,38 
which was then entered into the standard meta-analytic 
model described above. For further information regard-
ing methods see supplementary information.
Results
A total of 1798 papers were identified. 21 of these met 
inclusion criteria (PRISMA flow diagram in supplemen-
tary eFigure 2).
Studies of the Whole Striatum
21 studies of individuals with schizophrenia met inclu-
sion criteria (see table  1 for study details). The studies 
included a total of 269 patients (256 with a diagnosis of 
schizophrenia, 3 schizoaffective disorder, and 10 a mix-
ture of schizophrenia/ schizophreniform disorder) and 
313 controls. Presynaptic dopamine function was signif-
icantly elevated in individuals with schizophrenia rela-
tive to controls with a summary effect size of 0.68 (see 
figure 2, 95% CI 0.44–0.91; P < .001). Egger’s regression test 
was not significant (z = 1.21, P = .23), indicating publication 
bias was unlikely. Visual inspection of the funnel plot poten-
tially suggested asymmetry (supplementary eFigure 3), but 
a trim and fill analysis did not indicate any missing studies. 
The I2 value was 42.5%, suggesting a low to moderate level 
of heterogeneity. Subgroup meta-analysis of studies of pre-
dominantly drug naïve patients, and of patients who were 
receiving antipsychotic treatment, found a greater effect 
size in drug naïve patients (g = 0.78, P < .001 and .64, P 
< .001 respectively, see supplementary eFigure 5) but this 
difference was not statistically significant (P = .59). Studies 
using a challenge or depletion paradigm (g = 0.95, P < .001) 
showed a greater effect size when compared to those using 
labeled L-DOPA (g = 0.52, P < .001), and this difference 
was statistically significant (P  =  .049, see supplementary 
eFigure6). Neither scan time (P =  .44) nor the use of an 
arterial input function (P = .55) was significantly associated 
with magnitude of effect size in the labeled L-DOPA studies. 
Meta-regressions of effect sizes against age (P = .29), total 
symptoms (P = .16), and positive symptoms (P = .39) were 
not significant.
Studies of Limbic, Associative, and Sensorimotor 
Subdivisions
Seven studies of individuals with schizophrenia reported 
associative, sensorimotor and limbic subdivisions. These 
reported data on a total of 104 patients with schizophre-
nia (schizophrenia or schizophreniform disorder), and 
174 controls. All 7 studies used the subdivision defini-
tions proposed by Mawlawi et al,21 and Martinez et al.20
Significant differences were found between patients 
and controls for associative (schizophrenia – g  =  0.73, 
P  =  .002) and sensorimotor (schizophrenia – g  =  0.54, 
P = .009) subdivisions, but not for the limbic subdivision 
(schizophrenia – g = 0.29, P =  .09) (see figures 3A–C). 
The results for the associative subdivision showed the 
greatest heterogeneity (I2  =  58.3%), with sensorimotor 
(I2 = 37.7%), and limbic subdivisions (I2 = 29.5%) show-
ing relatively low levels of heterogeneity.
In individuals with schizophrenia, the difference between 
associative and limbic subdivisions was significantly greater 
in patients compared to controls (see figure 3C; effect size, 
g = 0.38, P = .004). Presynaptic dopaminergic function in 
schizophrenia was also significantly greater in the sensori-
motor compared to the limbic subdivision compared to the 
difference in controls (g = 0.29, P =  .03). There were no 
significant patient-control differences as regards the com-
parisons between dopamine function in the associative and 
sensorimotor subdivision (g = 0.08, P = .55). These com-
parisons showed low levels of heterogeneity (associative-
limbic I2 = 25.5%, other comparisons I2 = 0).
Discussion
Our main finding is that individuals with schizophrenia 
display greater elevation in dopaminergic functioning 
in the dorsal (sensorimotor and associative) relative to 
limbic striatum compared controls (figure 3). Moreover, 
there was no significant difference in presynaptic dopa-
minergic functioning between patients and controls for 
the limbic subdivision. This is, to our knowledge, the first 
study to meta-analyze differences between functional 
subdivisions of the striatum. Our analysis of the whole 
striatum included 8 additional studies published since 
previous reviews but is consistent with their findings in 
showing an increase in schizophrenia.1,3
Methodological Considerations
Moderate heterogeneity was seen in the studies of indi-
viduals with schizophrenia. Methodological factors such 
as differences in the resolution of scanners, measurement 
time, experimental paradigm, and modeling technique 
may contribute to this heterogeneity. In addition, dif-
ferences in the clinical characteristics of patients could 
contribute to between study heterogeneity, given findings 
that increased dopaminergic activity is linked to acute psy-
chosis.45,57,58 Some studies included antipsychotic treated 
patients. However, our sub-analysis in antipsychotic free/
naïve patients showed no statistically significant difference 
between these groups, and the elevation in presynaptic 
dopamine function was numerically larger in naïve patients 
than in antipsychotic treated patients, indicating antipsy-
chotic treatment is unlikely to account for the elevation we 
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see. Moreover chronic antipsychotic treatment may reduce 
dopamine synthesis capacity in some patients.59
We combined studies using challenge and depletion par-
adigms with those using radiolabeled DOPA. While there 
is some evidence that results from challenge paradigms are 
directly related to results from radiolabeled DOPA stud-
ies,60,61 it should be recognized that these measures are 
indexing different, albeit related, aspects of dopaminer-
gic function, and could be influenced by different factors. 
Interestingly our sensitivity analysis found that effects were 
greater for the challenge/depletion studies (supplementary 
efigure  6), which could suggest that these aspects of the 
dopamine system are particularly affected in schizophrenia.
Another factor contributing to heterogeneity could 
be the inclusion of individuals with treatment resistant 
schizophrenia, or with co-morbid substance dependence, 
given recent findings these groups may show reduced pre-
synaptic dopamine functioning.26,28,29,62 While we excluded 
studies specifically including these patients, many studies 
pre-dated these recent findings and did not specify these 
as exclusion criteria. As such it is likely that some of the 
included studies may have contained treatment resistant 
patients; indeed 2 studies report including patients tak-
ing clozapine.9,46 However this would, if  anything reduce 
effect sizes given treatment resistant patients do not seem 
to show presynaptic dopamine elevation.26,54
We examined the difference between subdivisions, as, in 
the absence of individual patient data, this measure can 
be more accurately estimated than the ratio between sub-
divisions. A potential drawback of our measure is that if, 
eg, associative values are greater than limbic values, then 
a uniform proportionate increase in dopaminergic func-
tion across the whole striatum in the clinical group would 
lead to a greater absolute increase in the associative stria-
tum, and thus give a larger associative-limbic difference. 
In our case, however, only 2 of the 7 control groups had a 
value for the associative region that was greater than the 
limbic value.31,37 Therefore, if  anything, effects related to 
general increases in striatal functioning would reduce the 
magnitude of our findings.
When examining the differences between subdivisions, 
the assumed correlation between subdivisions has an 
influence on the precision of the estimated magnitude of 
difference between subdivisions, with a stronger correla-
tion leading to larger effect sizes. The correlation coef-
ficient we employed, however, was conservative, using the 
lowest of the correlation coefficients between subdivi-
sions that we found in individual participant data. Using 
the largest coefficient of 0.87 gave an effect size of 0.50 
(P = .01 for associative limbic measure, and 0.29 (P = .01) 
for the sensorimotor-limbic measure (supplementary efig-
ure 5). Thus, the differences we report may underestimate 
the magnitude of the true difference.
The limbic striatum has a smaller volume than either the 
associative or sensorimotor subdivisions. As a result it is 
more susceptible to partial volume effects whereby its true 
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activity may be diluted by spill over and spill in from adja-
cent regions.63 However, given that there is no consistent 
evidence of reduced limbic striatal volumes in schizophre-
nia this would be expected to affect measures in patients 
and controls equally.64–67 Moreover one study employed 
partial volume correction and found a significant elevation 
in the associative striatum, but not in the limbic striatum in 
schizophrenia and clinical high risk groups relative to con-
trols,52 consistent with our meta-analytic findings. The fact 
that measures of dopamine functioning in the limbic stria-
tum may be less reliable compared to measures in other sub-
divisions does mean, however, that it is possible the reduced 
limbic effect size (figure 3A) could be at least partially due 
to the increased noise inherent in measuring this region.22,68 
This possibility is supported by some26,52 (but not all31,37,54) 
studies where the variance of the limbic measure, is notice-
ably greater than the variance of the associative measure.
Neither partial volume effects, nor reduced signal-to-
noise, however, would account for the patient-control dif-
ferences found when examining subdivision differences 
directly (figure 3B). In this case we are, eg, looking at lim-
bic-associative differences in patients, and comparing this 
to the limbic-associative differences in controls. A reduc-
tion in signal-to-noise for the limbic measure will there-
fore affect patient and control findings equally, and will 
not bias the results. This means that while the reduced 
reliability of limbic measurements may increase the risk 
of a false negative, in this specific analysis it will not 
increase the likelihood of a false positive.
The Anatomical Locus of Dopaminergic Dysfunction in 
Psychosis
Our meta-analysis confirms, using a larger sample, the 
previous meta-analytic findings of increased presynaptic 
dopamine functioning in schizophrenia in the striatum.1 
Moreover, our meta-analysis extends understanding 
of the nature of dopamine dysfunction in psychosis by 
showing that the degree of dopaminergic dysfunction 
varies across the striatum, and identifies the dorsal stria-
tum as the predominant locus of dopamine dysfunction 
in psychosis. Although patients showed no significant 
alteration in the limbic striatum relative to controls, we 
cannot rule out the possibility of a small difference in this 
Fig. 2. Forest plot of studies investigating presynaptic dopaminergic function in the whole striatum for individuals with schizophrenia. 
The forest plot shows the effect size (hedges g) and 95% CI for the difference between patients and controls. There is a significant 
elevation in schizophrenia with a summary effect size of 0.68.
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subdivision. Nevertheless, in patients the dorsal to ventral 
balance was significantly shifted dorsally in patients when 
compared to controls. While a small mesolimbic abnor-
mality may exist, overall these findings are not consistent 
with a hypothesis which proposes that the predominant 
locus of dopamine dysfunction is the limbic striatum.
Our findings thus suggest that models highlighting a 
primary role for excessive mesolimbic dopamine trans-
mission in psychosis may need to be revised.12–14,29 The 
associative subdivision receives dopaminergic innerva-
tion from the substantia nigra,12 suggesting that nigros-
triatal pathways may be disrupted in schizophrenia. This 
hypothesis is in keeping with findings of increases in 
some,31,48 although not all,10 aspects of dopamine func-
tioning within the substantia nigra in schizophrenia. 
The elevation was greatest in the associative striatum, 
although this was not significantly greater than the eleva-
tion in the sensorimotor striatum.
It should be noted, that while our findings support 
the hypothesis that dopaminergic functioning within the 
associative striatum may be abnormal in schizophrenia, 
this does not preclude the possibility that the primary site 
of dysfunction exists in another brain region.5 The associ-
ative part of the dorsal striatum receives projections pre-
dominantly from dorso-lateral prefrontal cortex.13 Thus 
the dorsal locus of dopamine abnormality is consistent 
with the hypothesis that frontal cortical dysfunction 
underlies striatal dopamine abnormalities,16,69 although 
causality remains to be established in clinical studies.
Our findings also question the proposal that mesolimbic 
selectivity is a desirable property for pharmacological treat-
ments of schizophrenia,70 and suggest instead that selectivity 
for the dorsal, particularly associative, striatum may show 
advantages in both efficacy and tolerability. Treatment strate-
gies may be able to make use of the neurochemical distinctions 
found across striatal subdivisions. For example, dopamine 
 
(c)
Fig. 3. Studies of presynaptic dopamine function in individuals with schizophrenia by functional subdivisions. Significant elevations 
are seen for the associative and sensorimotor, but not limbic subdivisions. In schizophrenia the associative-limbic and sensorimotor-
limbic differences are significantly greater in patients than in controls. (A) Effect size and 95% CI of difference in dopamine function 
in schizophrenia between patients and controls showing significant elevations in patients in associative (g = 0.73) and sensorimotor 
(g = 0.54) subdivisions but not limbic. (B) Effect sizes and 95% CIs of subdivision differences in schizophrenia between patients and 
controls. Patients show significantly greater associative-limbic (d = 0.38) and sensorimotor-limbic (d = 0.29) differences compared to 
controls. (C) Magnitude of patient-control differences in presynaptic dopamine functioning for striatal subdivisions in individuals with 
schizophrenia (*P < .05 for patient-control comparison), error bars represent 1 SE).
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transporter densities are greater in the ventral, compared to 
dorsal, striatum.71 Due to this variable distribution, combi-
nation therapy with a dopamine reuptake inhibitor and D2 
antagonist could potentially reduce dopaminergic neuro-
transmission to a greater degree in the dorsal, as opposed to 
ventral striatum. There are potential risks to this approach, 
but evidence suggests that in some patients it may have ben-
efits for the amelioration of negative symptoms.72
In conclusion, current molecular neuroimaging studies 
suggest that in individuals with schizophrenia the major 
locus of dopamine dysfunction is the dorsal striatum, 
and significant elevations were not seen in the limbic stri-
atum. These findings are inconsistent with the mesolim-
bic hypothesis of schizophrenia, and suggest treatments 
showing nigro-striatal rather mesolimbic selectivity may 
have better efficacy and tolerability.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin online.
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